Advaxis announces publication of preclinical research with ADXS-PSA Advaxis.
John Rothman, EVP of Science and Procedures at Advaxis.. Advaxis announces publication of preclinical research with ADXS-PSA Advaxis, Inc., , a leader in developing the next generation of immunotherapies for malignancy and infectious illnesses, announced the publication of preclinical research with ADXS-PSA , Advaxis’ Lm-LLO immunotherapy targeting the PSA antigen connected with prostate cancer. Chandan Guha and his laboratory at Montefiore Medical Center, Bronx, NY. The paper titled Mixed immunotherapy with Listeria monocytogenes-based PSA radiation and vaccine therapy qualified prospects to a therapeutic response in a murine style of prostate cancer by Hannan R, Zhang H, Wallecha A, Singh R, Liu L, Cohen P, Alfieri A, Rothman J, and Guha C., has been e-published ahead of print in the journal Tumor Immunology Immunotherapy.Related StoriesStopping cholesterol medicines before surgery may increase risk of death during recoveryFour microRNAs appear to play critical functions in controlling cholesterol, triglyceride metabolismDisclosing genetic risk for CHD outcomes in lower low-density lipoprotein cholesterolThey after that implanted inhibitor pellets in mice with a human gene that leads to amyloid plaque formation. Examination of brain cells after two months of treatment discovered that mice getting the ACAT inhibitor had 90 % less plaque than do transgenic mice who received placebo pellets. The outcomes were more dramatic in female mice even, who generally develop plaques earlier than males do.